The groundbreaking success of the copyright undeniably reshaped the medication landscape, but investing in companies primarily reliant on off-patent versions presents a challenging picture. Despite early returns were substantial, the cessation of patents and the appearance of less expensive alternatives have eroded sales. Consequently, a thorough e